M. Drent (Maastricht, The Netherlands), D. Valeyre (Paris, France)
Methotrexate vs azathioprine in chronic sarcoidosis
A.D.M. Vorselaars, W.A. Wuyts, V.M.M. Vorselaars, P. Zanen, V.H. Deneer, M. Thomeer, J.C. Grutters (Nieuwegein, Utrecht, Netherlands; Leuven, Hasselt, Belgium)
|  |
Concentration of sFas in bronchoalveolar lavage fluid of smoking patients with sarcoidosis
T. Urbankowski, A. Safianowska, R. Krenke, I. Knyziak-Medrzycka, J. Domagala-Kulawik (Warsaw, Poland)
|  ![]()  ![]() |
Association study of ANXA11-R230C with sarcoidosis
F. Bardaka, Z. Daniil, K. M. Antoniou, A. Mamara, F. Malli, K. I. Gourgoulianis, A. E. Germenis, M. Speletas (Larissa, Heraklion, Greece)
| |
HLA-DRB1 allele distributions in Danish sarcoidosis patients. Increased prevalence of HLA-DRB1*15
N. Milman, C.B. Svendsen, T. van Overeem Hansen, L. Ryder, K.R. Larsen (Copenhagen O, Copenhagen S, Denmark)
| |
Whole-body magnetic resonance imaging in sarcoidosis to assess extrapulmonary organ involvement
K. Hostettler, U. Studler, V. Bratu, A. Fischmann, M. Tamm (Basel, Switzerland)
| ![]() ![]() |
HLA-DPB1 and chronic sarcoidosis
A. Wennerström, A. Pietinalho, J. Lasota, K. Salli, M.L. Lokki, O. Selroos (Helsinki, Raasepori, Finland; Vejbystrand, Sweden)
|  ![]() ![]() |
Evaluation of ANXA11 rs1049550 SNP linkage with sarcoidosis susceptibility
A. Morais, B. Lima, S. Tafulo, M. Peixoto, H. Alves, N. Melo, P. Mota, A. Marques, L. Delagado (Oporto, Portugal)
| ![]() ![]() |
Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease
R. Baughman, D. Culver, F. Cordova, M. Padilla, K. Gibson, E. Lower, P. Engel (Cleveland, Philadelphia, New York, Cincinnati, United States Of America)
| ![]() ![]() |